| One
of the leading sectors of high tech investment
in startups, following the burst of the bubble,
has been the medical device sector. The number
of IPO's has grown dramatically from 2004 and
the number of acquisitions by a large players
such as J&J and Guidant also grown significantly.
Devices for new types of stents, measurement
devices for blood oxygen or blood glucose sugar,
surgical devices and many others are being developed
by new startups in the hope of achieving major
successes and profitable exists. What is unique
about investment in medical devices? What issues
are specific to the success or failure of medical
device startups? (e.g. regulatory issues, insurance
reimbursement, etc.). What are the promising
opportunities in medical devices? What are the
growth segments in the market?, What are the
longer term prospects for such investments?
IPO Vs. M&A, what’s the right strategy?
These and other questions will be discussed,
success stories and failures will be shared
and debates will be encouraged.
|
|
|
Schedule
| 5:30PM-6:30PM |
Poster Sessions/ Buffet Dinner/ Networking |
| 6:30PM-7:30PM |
Startup Company Presentations / Q & A |
| 7:30PM-8:00PM |
Break |
| 8:00PM-9:00PM |
Panel
Discussion |
| Topic:
"The
Future of Medical Devices: Innovations,
Market Growth and Exit Models" |
| 9:00PM-9:30PM |
Discussion |
|
|
Moderator:
Gerald Jay Sanders, Managing
Director ,San
Francisco ScienceTM |
|
Gerald
Jay Sanders |
Gerald
Jay (“Jerry”) Sanders is a guest
faculty member (Entrepreneurship) at Oxford
University’s Saïd Business School
(“Associate Fellow”) and an advisor
and lecturer at the Paris Chamber of Commerce
and Industry and at its affiliated business
school, Advancia. The Jerry Sanders Case, a
popular Harvard Business School “Entrepreneurship”
case, is taught as part of the MBA program at
Harvard, Oxford, Stanford, Kellogg (Northwestern),
and MIT. Jerry
has an extensive background in medical technology
incubation, development and international cooperation.
As President of the Shaw Group and later as
Managing Director of his own San Francisco Science
Group, Sanders has acquired and developed medical
devices in the United States, Germany, Argentina,
Israel and the Former Soviet Republics. He has
sold companies and partnered with industry giants,
among them Boston Scientific, Johnson &
Johnson, Abbot and Baxter.
|
| Panelist:
Dana Mead, Partner,
Kleiner Perkins Caufield & Byers |
|
Dana
Mead |
For
the past 23 years, Dana's career has focused on
identifying new medical technologies. He has worked
with physician thought leaders around the world
representing 10 different medical specialties.
At KPCB, Dana leverages experience gained from
his venture-funded, start-up management roles
and board participation to support entrepreneurs
and innovators dedicated to making a real difference
in the lives of millions suffering from life-limiting
disease. Prior to joining KPCB, Dana was President
of Guidant Vascular Intervention, a fully integrated
billion dollar division with over 4500 employees.
Since joining Guidant, he held positions as Vice
President and General Manager, Cardiac & Vascular
Surgery; Vice President and General Manager, Stents,
Vascular Intervention Group; President, Japan
and A/P Operations based in Tokyo; and Vice President,
Corporate Relations and Policy with responsibility
for investor relations, corporate communications,
corporate marketing and public policy initiatives.
Prior to joining Guidant, Dana worked in various
sales and marketing roles at Allergan, Inc. and
Johnson & Johnson. Dana serves on the boards
of the California Healthcare Institute (CHI),
the Cardiovascular Research Foundation (CRF),
AesThera, Inc., Sonitus, Amigo Therapy, OtisMed
Corporation and Lucille Packard Children's Hospital
(LPCH). |
| Panelist:
Scott
J. Wolf, M.D. Partner,
Prospect Venture Partners |
Scott
J. Wolf
|
Prior
to joining Prospect, Scott was a Vice-President
at Frazier Healthcare Ventures, where he was involved
in medical device investments across all stages
from seed to commercialization. While at Frazier,
Scott founded and served as CEO and Director of
Juniper Medical, a device startup developing non-invasive
methods of bodysculpting and cellulite therapy,
and Primaeva, a startup developing devices for
aesthetic procedures. Prior to joining Frazier,
Scott was a founding partner of Scout Medical
Technologies, a venture capital incubator developing
new medical device companies. While at Scout,
Scott co-founded three portfolio companies: Cardiac
Dimensions, Archus Orthopedics, and Endogastric
Solutions. Prior to Scout, Scott was President
of Itasca Ventures, a medical device incubator
funded by Medtronic, where he was involved in
founding a number of companies. Scott currently
serves on the Board of Directors of Cabochon Aesthetics
and is a Board Observer on Kythera Biopharmaceuticals.
Scott is an inventor on numerous issued and pending
patents in the medical device field. He received
his M.D. from George Washington University and
his B.A. from the University of Pennsylvania. |
| Panelist:
Vance Vanier, Partner,
Mohr Davidow Ventures
|
|
Vance
Vanier |
Vance
Vanier brings to MDV a diverse blend of healthcare,
industry, and international experiences. He focuses
on life science and online health investments.
In addition to investing, Vance also works to
develop MDV's life science companies serving in
virtual CMO and business development roles. He
is a member of the clinical faculty in the Division
of Emergency Medicine at Stanford Medical Center.
He received an M.D. from the Johns Hopkins School
of Medicine and did his residency training at
UCSF and Highland Hospital. Prior to joining MDV
he received an MBA from Stanford University, worked
in corporate development at Nektar Therapeutics,
and traveled to Kosovo after the war to work with
the WHO in creating the nation's first ambulance
system. Vance did his undergraduate work at Stanford
where he received dual bachelor's degrees with
honors. |
| Panelist:
Jay Watkins, Managing
Director ,
De Novo Ventures |
Jay
Watkins
|
Mr.
Watkins was a co-founder of Origin Medsystems,
a venture funded medical technology start-up that
was purchased by Eli Lilly & Company in 1992.
When Eli Lilly divested its medical device businesses
to form Guidant in 1995, he became a member of
the corporation's management committee, serving
in this role from 1995-2002. During this time,
he served as president of numerous divisions,
including the Minimally Invasive Surgery Group.
In addition, Mr. Watkins was the President of
Compass, Guidant Corporation's corporate business
development and new ventures group. Prior to founding
Origin, Mr. Watkins held management positions
in several start-ups, including Microgenics Corporation,
and was a consultant with the international consulting
firm of McKinsey & Company. He has been a
member of the board of directors of several public
companies, including Gynecare, Cardiogenesis,
and Rita Medical. Jay also serves on the Stanford
University School of Engineering Advisory Council.
Mr. Watkins received his MBA from Harvard Business
School and his undergraduate degree from Stanford
University. |
|
